β-D-Glucan Level of 117 pg/mL in a Kidney Transplant Patient
A Fungitell level of 117 pg/mL in your kidney transplant patient is suggestive but not diagnostic of invasive fungal infection and should prompt immediate clinical correlation with symptoms, imaging, and consideration of empiric antifungal therapy while pursuing additional diagnostic workup.
Interpretation of the Result
The Fungitell assay uses a cutoff of ≥80 pg/mL as positive 1. Your patient's value of 117 pg/mL exceeds this threshold, but this single result requires careful interpretation in the transplant context.
Test Performance Characteristics
The β-D-glucan assay has moderate sensitivity (75-80%) and specificity (80%) for invasive candidiasis 1. However, the positive predictive value is problematic—in solid organ transplant recipients, it ranges from only 35% 2, meaning the majority of positive results may be false positives.
Key limitation: The negative predictive value is excellent at 93% 2, so a negative test is more useful for ruling out infection than a positive test is for ruling it in.
Clinical Decision Algorithm
Step 1: Assess for Clinical Evidence of Invasive Fungal Infection
Look specifically for:
- Fever unresponsive to antibiotics for >96 hours
- New pulmonary infiltrates on imaging (nodules, cavitation, halo sign)
- Intra-abdominal fluid collections or peritonitis
- Skin lesions (nodules, eschars)
- Neurological symptoms (headache, altered mental status)
- Retinal lesions on fundoscopic exam
Step 2: Identify Risk Factors for False Positivity
β-D-glucan false positives are common in transplant patients due to 1:
- Hemodialysis (especially with cellulose membranes)
- Intravenous immunoglobulin (IVIG) administration
- Gauze exposure during specimen collection
- Bacterial infections (especially gram-positive bacteremia)
- Severe mucositis or enterocyte damage
Step 3: Determine Need for Serial Testing
A single positive result should NOT trigger antifungal therapy alone 3. The optimal diagnostic approach requires ≥2 sequential positive results (≥80 pg/mL) to improve accuracy to 81.3% with sensitivity of 86.8% 3.
- Repeat testing in 48-72 hours
- If second test is also positive AND clinical suspicion exists, proceed with treatment
- If second test is negative, consider false positive from the causes above
Step 4: Initiate Empiric Therapy Based on Risk Stratification
Start empiric antifungal therapy immediately if:
- Patient has persistent fever >96 hours despite antibiotics
- New pulmonary infiltrates or other organ involvement on imaging
- Two positive β-D-glucan results
- High-risk period (first 3 months post-transplant, recent rejection treatment)
Recommended empiric regimen:
- Echinocandin (caspofungin, micafungin, or anidulafungin) as first-line for suspected invasive candidiasis
- Consider voriconazole if aspergillosis is suspected based on imaging (nodules, cavitation)
Critical drug interaction: If using azole antifungals, tacrolimus dose must be reduced by two-thirds for voriconazole and one-third for fluconazole 4. Echinocandins have minimal interaction with tacrolimus 4.
Additional Diagnostic Workup
While awaiting repeat β-D-glucan:
- Blood cultures (at least 2 sets from different sites)
- CT chest if pulmonary symptoms
- CT abdomen/pelvis if abdominal symptoms
- Fundoscopic examination for Candida endophthalmitis
- Consider galactomannan if aspergillosis suspected (though sensitivity is low at 30-56% in solid organ transplant 5)
Important Caveats
Prophylactic antifungals reduce test sensitivity: If your patient is on fluconazole or echinocandin prophylaxis, β-D-glucan levels may be falsely lowered 1. Conversely, breakthrough infections can still occur with positive β-D-glucan despite prophylaxis.
Timing matters: In one liver transplant study using preemptive treatment at β-D-glucan >40 pg/mL, mortality from fungal infection was only 0.6%, though 28% experienced drug-related adverse effects 2. The lower threshold and preemptive approach may be justified in very high-risk patients.
Do not use for routine surveillance: Recent data shows β-D-glucan surveillance in transplant patients on antifungal prophylaxis has 0% sensitivity and 0% PPV due to high false-positive rates when pretest probability is low 6. Only order when clinical suspicion exists.
Monitoring During Treatment
If antifungal therapy is initiated:
- Tacrolimus levels should be checked within 48-72 hours if azole started
- Repeat β-D-glucan weekly: Declining levels correlate with treatment response 1
- Renal function and electrolytes (hypokalemia, hypomagnesemia common with amphotericin)